As a result of the inconclusive VE data (as detailed in the preceding section), immunogenicity studies were important in guiding the recommendations of optimal timing of vaccination against pertussis in pregnancy in different countries, assuming that higher concentrations of anti-B. pertussis antibodies, especially those against PT, are associated with higher clinical protection from clinical disease [65]. The gene discussed is F2; the disease is pertussis.